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1. INTRODUCTION 1 
Drugs are rarely administered solely as pure chemical substances, but are almost given as 
formulated preparations. The principle objective of dosage form design is to achieve a 
predictable therapeutic response to a drug included in the formulation. 
Before a drug substance can be successfully formulated in to a dosage form, many factors must 
be considered. These factors can be broadly grouped in to three categories. 
 Biopharmaceutical considerations (Factors affecting absorption of drugs) 
 Drug related factors (Physical and chemical properties of a drug) 
 Therapeutic considerations (Disease to be treated and patient factors) 
 
Among various orally administered dosage forms (tablets, capsules, syrup, solution etc…), the 
tablet dosage form is the most widely used. 
Solid medicaments may be administered orally as powders, pills, cachets, capsules or tablets. 
These dosage forms contain a quantity of drug which is given as a single unit and they are known 
collectively as solid unit dosage forms, even in the case of sustained action preparations which, 
technically, contain the equivalent of several normal doses of drug .The stringent formulation 
requirements of modern medicaments, the many advantages of tablet and capsule medication, 
coupled with expanding health services and the commitment need for large-scale economic 
manufacture, have led to a steady decline in the prescribing of powders and pills. 
Tablets and capsules, on the other hand, currently account for well over two third of the total 
number and cost of medicines produced all over the world.  
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1.1 Tablets 
Tablet is defined as a compressed solid dosage form containing medicaments with or without 
excipients.  
According to the Indian Pharmacopoeia Pharmaceutical tablets are solid, flat or biconvex 
dishes, unit dosage form, prepared by compressing a drugs or a mixture of drugs, with or without 
diluents. They vary in shape and differ greatly in size and weight, depending on amount of 
medicinal substances and the intended mode of administration. It is the most popular dosage 
form and 70% of the total medicines are dispensed in the form of Tablet. All medicaments are 
available in the Tablet form except where it is difficult to formulate or administer.  
 
Fig 1.1.Shows schematic flow chart of tablet post administration 
They vary greatly in shape, size and weight which depend upon amount of medicament used and 
mode of administration. They also vary in hardness, thickness, disintegration and dissolution 
characteristics and in other aspects depending upon their intended use and method of 
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manufacture. Tablets are the most widely used solid dosage form of medicament. Because of 
their advantages their popularity is continuously increasing day by day. 
1.1.1 Advantages 2 
They are unit dosage form and offer the greatest capabilities of all oral dosage form for the 
greatest dose precision and the least content variability.  
 Cost is lowest of all oral dosage form  
 Lighter and compact  
 Easiest and cheapest to package and strip 
 Easy to swallowing with least tendency for hang-up 
 Sustained release product is possible by enteric coating 
 Objectionable odour and bitter taste can be masked by coating technique 
 Suitable for large scale production 
 Greatest chemical and microbial stability over all oral dosage form 
 Product identification is easy and rapid requiring no additional steps when employing an 
embossed and/or monogrammed punch face. 
1.1.2 Disadvantages 
In spite of all these advantages, tablet also possesses some disadvantages. The 
disadvantages of tablets include the following 
 Some drugs resist compression in to dense compacts, owing to their amorphous 
nature or flocculent, low density character. 
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 Drugs with poor wetting properties, slow dissolution properties, intermediate to 
large dosages, optimum absorption high in the GIT or any combination of these 
features may be difficult or impossible to formulate and manufacture as a tablet 
that will still provide adequate or full drug bioavailability. 
 Bitter tasting drugs, drug with obnoxious odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation / entrapment prior to 
compression / coating. 
 
1.2 CLASSIFICATION OF TABLETS 3 
A. Classification based on mode of administration 
 Tablets to be swallowed  
  Chewable tablets 
 Tablets used in oral cavity 
 Buccal tablets 
 Sublingual tablets 
 Troches and lozenges 
 Dental cones 
 Tablets administered other than oral route 
 Implants 
 Vaginal tablets / suppositories 
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B. Classification based on drug manufacturing process 
 Standard compressed tablets 
 Multiple compressed tablets 
 Compression-coated tablets 
 Layered tablets 
 Coated tablets 
 Molded tablets (Tablet triturates) 
C. Classification based on drug release profile 
 Fast dissolving tablets 
 Immediate release tablets 
 Controlled Release tablets (Sustained Release Tablets) 
 Delayed Release tablets (Enteric coated tablets) 
D. Tablets used to prepare solutions 
 Effervescent tablets 
 Dispersible tablets 
 
1.3 BILAYER TABLETS 4 
Compressed tablets are defined as solid dosage forms made by compaction of the formulation 
containing the drug and certain fillers or excipients selected to aid in the processing and 
properties of the drug product. 
Multilayer tablets are tablets made by compressing several different granulations fed in to a die 
in succession, one on top of another, in layer. Each layer comes from a separate feed frame with 
individual weight control. Rotary tablet presses can be set up for 2 or 3 layers. More are possible 
PADMAVATHI COLLEGE OF PHARMACY-DPI Page 6 
 
but the design becomes very special. Ideally a slight compression of each layer and individual 
layer ejection permits weight checking for control purposes. 
1.3.1 Advantages of Bilayer tablets 
The primary potential advantages of tablets are, 
 They are the unit dosage forms, which offer the great capabilities of all oral dosage forms 
for the greatest dose precision and the least content variability 
 The cost is lower of all oral dosage forms 
 They are the lightest and most compact of all 
 They are in general the easiest and cheapest to packaging and shipment 
 Product identification is potentially the simplest and cheapest, requiring no additional 
processing steps when employing an embossed or monogrammed punch face 
 They may provide the greatest case of swallowing with the least tendency for hang up 
above the stomach, especially when coated, provided the tablet disintegration is not 
excessively rapid 
 They lend themselves to certain special profile products, such as enteric or delayed 
release products 
 They are better suited to large scale production than with other unit oral dosage forms 
 They have the best combined properties of chemical, mechanical and microbiological 
stability of all the oral forms 
 
1.3.2 Layer thickness 
 Layer thickness can be varied within reasonable proportions within the limitations of the 
tablet press. Thickness is dependent on the fineness of the granulation. 
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1.3.2.1 Sizes and Shapes  
 Size is limited by the capacity of the machine with the total thickness being the same as 
for a single layer tablet. Many shapes other than spherical are possible and are limited only by 
the ingenuity of the die maker. However, deep concavities can cause distortion of the layers. 
Therefore standard concave and flat face beveled edge tooling make for the best appearance, 
especially when layers are of different colors. 
 
1.3.3 Granulations 
For good quality tablets with sharp definition between the layers, special care must be taken as 
follows, 
 Dust fines must be limited. Fines smaller than 100 meshes should be kept as a 
minimum 
 Maximum granule size should be less than 16 meshes for a smooth, uniform scrap off 
at the die. 
 Materials that smear, chalk or coat on the die table must be avoided to obtain clean 
scrape off and uncontaminated layers. 
 Low moisture is essential if incompatibilities are used. 
 Weak granules that break down easily must be avoided. Excessive amounts of 
lubrication, especially metallic stearates, should be avoided for better adhesion of the 
layers. 
 Formulation of the multilayer tablets is more demanding than that of single layer 
tablets for this reason, selection of additives is critical. 
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1.3.4 Tablet layer press 
A tablet multilayer press is simply a tablet press that has been modified so that it has two die 
filling and compression cycles for each revolution of the press. In short, each punch compresses 
twice, once for the first layer of a two layer tablet and a second time for the second layer. Three 
layer presses are equipped with three such compression cycles.  
There are two types of layer presses presently in the use- one in which each layer can be 
ejected from the press separately for the purpose of weight checking and the second in which the 
first layer is compressed so hard that the second layer will not bond to it or will bond so poorly 
that upon ejection the layers are easily separated for weighing. Once the proper 
adjustments have been made by adjusting the die fill, the pressure is adjusted to the 
proper tablet hardness and bonding of the layers. 
One hazard of layer tablet production is the lack of proper bonding of the layers. This can 
result in a lot of 100,000 tablets ending up as 200,000 layers after several days if the layers are 
not sufficient bonded. 
In a two layer tablet press, two hoppers above the rotary die table feed granulated material to two 
separate feed frames without intermixing. Continuous, gently circulation of the materials through 
the hoppers and that would otherwise carry over to the second layer and affect layer weight, 
appearance of the tablet. The same procedure is followed in the three layer press with three 
hoppers for the three granulations instead of two. 
Certain single layer or unit tablet presses are equipped with two pre-compression stations prior to 
the final compaction. This provides high speed production by increasing dwell time of the 
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material under pressure making for harder, denser tablets. Eg. Prolonged and immediate release 
tablet containing penta errythritol tetra nitrate two layer tablets   
 
1.4 FLOATING DRUG DELIVERY SYSTEM 5 
The design of floating drug delivery Systems (FDDS) should be primarily aimed to achieve more 
predictable and increased bioavailability. Now-a-days most of the pharmaceutical scientist is 
involved in developing the ideal FDDS. This ideal system should have advantage of single dose 
for the whole duration of treatment and it should deliver the active drug directly at the specific 
site. Scientists have succeeded to develop a system and it encourages the scientists to develop 
control release tablet. Control release implies the predictability and reproducibility to control the 
drug release, drug concentration in target tissue and optimization of the therapeutic effect of a 
drug by controlling its release in the body with lower and less frequent dose.  Under certain 
circumstances prolonging the gastric retention of a delivery system is desirable for achieving 
greater therapeutic benefit of the drug substances. For example, drugs that are absorbed in the 
proximal part of the gastrointestinal tract, and the drugs that are less soluble or are degraded by 
the alkaline pH may benefit from the prolong gastric retention. In addition, for local and 
sustained drug delivery to the stomach and the proximal small intestine to treat certain 
conditions, prolonging gastric retention of the therapeutic moiety may offer numerous 
advantages including improved bioavailability, therapeutic efficacy and possible reduction of the 
dose size. Gastric emptying of dosage forms is an extremely variable process and ability to 
prolong and control the emptying time is a valuable asset for dosage forms, which reside in the 
stomach for a longer period of time than conventional dosage forms. Several difficulties are 
faced in designing controlled release systems for better absorption and enhanced bioavailability. 
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One of such difficulties is the inability to confine the dosage form in the desired area of 
the gastrointestinal tract. Drug absorption from the gastrointestinal tract is a complex procedure 
and is subject to many variables. It is widely acknowledged that the extent of gastrointestinal 
tract drug absorption is related to contact time with the small intestinal mucosa.      
Thus, small intestinal transit time is an important parameter for drugs that are incompletely 
absorbed. Basic human physiology with the details of gastric emptying, motility patterns, and 
physiological and formulation variables affecting the cosmic emptying are summarized.Gastro 
retentive systems can remain in the gastric region for several hours and hence significantly 
prolong the gastric residence time of drugs. Prolonged gastric retention improves bioavailability, 
reduces drug waste, and improves solubility for drugs that are less soluble in a high pH 
environment. It has applications also for local drug delivery to the stomach and proximal small 
intestines. Gastro retention helps to provide better availability of new products with new 
therapeutic possibilities and substantial benefits for patients. 
These have a bulk density lower than the gastric content. They remain buoyant in the stomach 
for a prolonged period of time, with the potential for continuous release of drug. Eventually, 
the residual system is emptied from the stomach. Gastric emptying is much more rapid in the 
fasting state and floating systems rely heavily on the presence of  food to retard emptying and 
provide sufficient liquid or effective buoyancy.6 Floating drug delivery systems are classified 
depending on the use of two formulation variables, effervescent and non-effervescent systems. 7 
 
1.4.1 Advantages of floating drug delivery systems  
Floating dosage systems form important technological drug delivery systems with gastric 
retentive   behaviour and offer several advantages in drug delivery. These advantages include: 
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 Floating dosage forms such as tablets or capsules will remains in the solution for 
prolonged time even at the alkaline pH of the intestine. 
 FDDS are advantageous for drugs meant for local action in the stomach eg: Antacids 
 FDDS dosage forms are advantageous in case of vigorous intestinal movement and in 
diarrhoea to keep the drug in floating condition in stomach to get a relatively better 
response. 
 Acidic substance like aspirin causes irritation on the stomach wall when come in 
contact with it hence; HBS/FDDS formulations may be useful for the administration 
of aspirin and other similar drugs. 
 The FDDS are advantageous for drugs absorbed through the  stomach eg: Ferrous 
salts, Antacids. Improved drug absorption, because of increased GRT and more time 
spent by the dosage form at its absorption site. 
 Controlled delivery of drugs. Minimizing the mucosal irritation due to drugs, by drug 
releasing slowly at controlled rate. 
 Treatment of gastrointestinal disorders such as gastroesophageal reflux.  
 Ease of administration and better patient compliance. 
 Site-specific drug delivery. 
1.4.2 Disadvantages of floating drug delivery systems  
 Floating systems are not feasible for those drugs that have solubility or stability 
problems in gastric fluids. 
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 Drugs such as Nifedipine, which is well absorbed along the entire GI tract and which 
undergo significant first-pass metabolism, may not be suitable candidates for FDDS 
since the slow gastric emptying may lead to reduced systemic bioavailability. Also 
there are limitations to the applicability of  FDDS for drugs that are irritant to gastric 
mucosa. 
 One of the disadvantages of floating systems is that they require a sufficiently high 
level of fluids in the stomach, so that the drug dosages form float therein and work 
efficiently. 
 These systems also require the presence of food to delay their gastric emptying. 
 Gastric retention is influenced by many factors such as gastric motility, pH and 
presence of food. These factors are never constant and hence the buoyancy cannot be 
predicted. 
 Drugs that cause irritation and lesion to gastric mucosa are not suitable to be 
formulated as floating drug delivery systems. 
 Gastric emptying of floating forms in supine subjects may occur at random and 
becomes highly dependent on the diameter and size. Therefore patients should not be 
dosed with floating forms just before going to bed 
1.4.3 Effervescent system  
A drug delivery system can be made to float in the stomach by incorporating a floating 
chamber which may be filled with vacuum,air or inert gas. The gas in the floating 
chamber can be introduced either by volatalization of an organic solvent or by the 
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effervescent reaction between organic acid and bicarbonate salts.  
 
1.4.3.1 Volatile liquid containing system 
The gastric retention time of a drug delivery system can be sustained by 
incorporating floatable chamber, which contains a liquid e.g. ether, cyclopentane, that  
gasify at body temperature to cause inflation of chamber in the stomach. These devices are 
osmotically controlled floating system.8 Intra gastric osmotically controlled drug  delivery 
system consist of an osmotic pressure controlled drug delivery device and an inflatable 
floating support in a bioerodible capsule. When the device reaches the stomach, bio 
erodible capsule quickly disintegrate to release the drug delivery system. The floating supports 
made up of deformable hollow polymeric bag containing a liquid that gassify at body 
temperature to inflate the bag. In stomach water is absorbed through the semipermeable 
membrane into the osmotic compartment to dissolve the salt. An osmotic pressure is thus 
created, which acts on the collapsible bag, and in turn forces the drug reservoir compartment 
to reduce it's volume and release the drug solution through the delivery orifice. 9 
 
 
 
 
 
 
 
Figu 1.2. Osmotically controlled drug delivery system. 
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1.4.3.2 Gas generating system  
These are matrix types of systems prepared with swellable polymers such as 
Methylcellulose and chitosan and various effervescent compounds, e.g. sodium 
bicarbonate, tartaric acid and citric acid. They are formulated in such a way that when in 
contact with the acidic gastriccontents,CO2 is liberated and gets entrapped in swollen 
hydrocolloids, which provides buoyancy to the dosage forms. A decrease in specific gravity 
causes the dosage form to float on the chyme.10    In single unit systems, such as capsules or 
tablets effervescent substances are incorporated in the hydrophilic polymer and CO2 bubbles 
are trapped in the swollen matrix. In vitro, the lag time before the unit floats is <1 min and 
the buoyancy is prolonged for 8 to 10 h. In vivo experiments in fasted dogs showed a mean 
gastric residence time increased up to 4 hr. Bilayer or multilayer systems have also been 
designed. Drug and excipients can be formulated independently and the gas generating unit 
can be incorporated into any of the layers. Further refinements involve coating the matrix with 
a polymer which is permeable to water, but not to CO2.The main difficulty of such formulation 
is to find a good compromise between elasticity, plasticity and permeability of polymer. It is 
difficult to control in situ acid base reaction and in turn drug release. 11 
 
 
 
 
 
Fig 1.3 Gas generating system: Schematic monolayer drug delivery system(a) Bilayer 
gas generating system, with (c) or without (b)semipermeable membrane. 
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1.4.3.3  Raft-forming system  
Here, a gel-forming solution (e.g. sodium alginate solution containing carbonates or 
bicarbonates) swells and forms a viscous cohesive gel containing entrapped CO2 bubbles on 
contact with gastric fluid. Formulations also typically contain antacids such as aluminium 
hydroxide or calcium carbonate to reduce gastric acidity. Because raft-forming systems 
produce a layer on the top of gastric fluids, they are often used for gastroesophageal reflux 
treatment.12  
 
 
 
 
Fig 1.4.Schematic illustration of the barrier formed by a raft-forming system 
 
1.4.4 Non-effervescent floating dosage form 
The most commonly used excipients in non-effervescent FDDS are gel-forming or highly 
swellable cellulose type hydrocolloids, polysaccharides, and matrix forming  
polymers such as polycarbonate, polyacrylate, polymethacrylate and polystyrene. One of the 
approaches to the formulation of such floating dosage forms involves intimate mixing of drug 
with a gel-forming hydrocolloid, which swells in contact with gastric fluid after oral 
administration and maintains a relative integrity of shape and a bulk density of less than unity 
within the outer gelatinous barrier.13  
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Hydrodynamically balanced system: On coming in contact with gastric fluid, the 
hydrocolloid in the system hydrates and forms a colloidal gel barrier around its 
surface. This gel barrier controls the rate of fluid penetration into the device and 
consequent release of the drug. As the exterior surface of the dosage form goes into the 
solution, the gel layer is maintained by the adjacent hydrocolloid layer becoming 
hydrated. The air trapped in by swollen polymer maintains density less than unity and 
confers buoyancy to these dosage forms. 
The hydrodynamically balanced system must comply with three major criteria- 
•    It must have sufficient structure to form cohesive gel barrier  
• It must maintain an overall specific density lower than that of gastric content 
• It should dissolve slowly enough to serve as reservoir for the delivery system.10 
The main drawback of HBS is pasivity of operation. It depends on the air sealed in the dry mass 
centre following hydration of the gelatinous surface layer and hence on the characteristics and 
amount of polymer. Effective drug delivery depends upon the balance between drug loading and 
effect of polymer on it's release profile.14 
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2. LITERATURE REVIEW 
 Yang L et.al,,., 15 (1996) developed various types of tablets (bilayered and matrix) 
which are having floating characteristics. Some of the polymers used are 
hydroxypropyl cellulose, hydroxypropyl methyl cellulose, crospovidone, sodium 
carboxymethyl cellulose and ethyl cellulose. Self-correcting floatable asymmetric 
configuration drug delivery system employs a disproportionate 3-layer matrix 
technology to control drug release. 
 
 Murata,Y et.al,,.,16 (2000) developed a floating alginate beds for stomach specific 
drug delivery were prepared. In this work, two types of alginate gel beds, 
ALGO (containing vegetable oil) and ALCS (containing chitosan) were prepared, 
which floated in gastric fluid if they contained a vegetable oil or air in their gel matrix 
and gradually released the drug metronidazole. The drug-release profile was not 
affected by the kind of chitosan contained in ALCS. When ALCS containing MZ 
was administered orally to guinea pigs, it floated on the gastric juice and released the 
drug into the stomach. Furthermore, the concentration of MZ at the gastric mucosa 
after administration of ALCS was higher than that in the solution, though the MZ 
serum concentration was the same regardless of which type of gel was administered. 
These release properties of alginate gels are applicable not only for sustained release 
of drugs but also for targetingthe gastric mucosa. 
 
 Ozdemir et.al,,., 17 (2000) developed floating bilayer tablets with controlled release 
for furosemide. This study was designed to enhance the bioavailability of furosemide 
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by  prolonging its duration in the stomach via the floating dosage forms with 
controlled release. All formulations were prepared as two-layer tablets. The first layer 
provided  floating and contained the mixture of sodium bicarbonate and citric acid to 
form air bubbles and HPMC K4M as a matrix material to retain the air bubbles. The 
second layer (release layer) provided controlled release of active material. It contained 
active material and HPMC K100M as hydrophilic matrix material. 
 Juan Manuel Llabot et.al,.,18 (2002) designed the mucoadhesive Bilayered of both 
immediate release and sustained release tablets of nystatin. The mucoadhesive tablet 
formulated in this work releases nystatin quickly from the lactose layer and then in a 
sustained way, during approximately 6 hours, from the polymeric layer. The mixture CB: 
HPMC 9:1 showed good in vitro mucoadhesion. A swelling-diffusion process modulates 
the release of nystatin from this layer. A non-Fickian (anomalous) kinetic was observed. 
 
 Dave B.S et.al,., 19 (2004) developed a floating drug delivery system of 
ranitidine hydrochloride. Guar gum, xanthan gum and hydroxypropyl 
methylcellulose were  evaluated for gel-forming properties. The effects of citric acid and 
stearic acid on  drug  release profile and floating properties were investigated by using 
full factorial design. The results indicated that a low amount of citric acid and a high 
amount of stearic acid favors sustained release of ranitidine hydrochloride from 
a gastroretentive  formulation. No significant difference was observed between the 
desired release profile and optimized batches. These studies indicate that the proper 
balance between a release rate enhancer and a release rate retardant can produce a 
drug dissolution  profile similar to a theoretical dissolution profile.  
PADMAVATHI COLLEGE OF PHARMACY-DPI Page 19 
 
 S. C. Basak et.al,,20 (2004) studied on controlled release HPMC matrix tablets of 
propanolol Hcl matrix tablets with HPMC polymer to control the release of drug 
with a view to develop twice daily sustained release dosage form. The resulting 
matrix tablets prepared with HPMC K4M fulfilled all the official requirements of 
tablet dosage forms. 
 
 Pandey H  et.al,,., 21 (2005) developed sustained release bilayer tablet of domperidone 
using hydrophilic matrix material such as HPMC, carbapol and poly-ethylene oxide. The 
results indicated that the formulation with HPMC could extend the drug release upto 
24hr. All the formulations show diffusion dominated drug release. 
 
 
 Muthusamy K, et.al,,.,22 (2005) developed preparation and evaluation of lansoprazole 
floating micropellets were reported.Floating micropellets of 1:1, 1:2 and 1:3 drug to 
carrier ratios were prepared using HPMC, MC and Chitosan as a carrier. All 
floating micopellet formulations showed good flow properties except formulation 
containing HPMC as coating material and packability. Drug loaded micropellets were 
found to float on simulated gastric fluid and simulated intestinal fluid for more than 12 
hour. Drug to chitosan ratio 1:1 showed good incorporation efficiency and high 
percentage in vitro release of lansoprazole from micropellets.  
 
 M. Chavanpatil  et.al,,., 23  (2005) developed a once-daily sustained release gastro 
retentive drug delivery system for ofloxacin by using different polymers such as psyllium 
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husk, hydroxypropyl methylcellulose K100M and crospovidone. In this work 
HPMC  K100M and psyllium husk were used as release retarding agents. 
Crospovidone was used as swelling agent. The in vitro drug release followed Higuchi 
kinetics and the drug release mechanism was found to be of anomalous or non-Fickian 
type. The high water uptake leading to higher swelling of the tablet supported the 
anomalous release mechanism of ofloxacin. The swelling properties were increased 
with increasing  crospovidone concentration and contributed significantly in drug 
release from the tablet matrix. 
 
 Narendra et.al,,.,24  (2006) developed an optimized bilayer gastric floating tablet 
containing metoprolol tartrate using soluble starch for immediate loading dose layer and 
HPMC was used for sustained release layer with SCMC was used for floating the tablet. 
Fickian release transport was confirmed as the release mechanism from the optimized 
formulation. The results demonstrate the feasibility of the model in the development of 
GFDDS. The results demonstrate the feasibility of the model in the development of 
GFDDS. 
 
 Vishnu M Patel G et.al,,.,25 (2007) studied the mucoadhesive bilayer tablets of 
propanolol hydrochloride using the bioadhesive polymers sodium alginate and Carbopol 
934P (CP) along with ethyl cellulose as an impermeable backing layer. Tablets 
containing Na-alginate and CP in the ratio of 5:1 (F2) had the maximum percentage of in 
vitro drug release without disintegration in 12 hours. The swelling index was proportional 
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to Na-alginate content and inversely proportional to CP content. The mechanism of drug 
release was found to be non-Fickian diffusion and followed zero-order kinetics. 
 
 Chinam Niranjan Patra et.al,,.,26 (2007) developed the bilayered tablets of propanolol 
hydrochloride using superdisintegrant sodium starch glycolate for the fast release layer 
and water immiscible polymers such as ethyl cellulose, Eudragit RLPO and Eudragit 
RSPO for the sustaining layer. The formulations gave an initial burst effect to provide the 
loading dose of drug followed by sustained release for 12 h from the sustaining layer of 
matrix embedded tablets. In vitro dissolution kinetics followed the Higuchi model via a 
non-Fickian diffusion controlled release mechanism after the initial burst release. 
 
 Girish S. Sonara et.al,,., 27 (2007) prepared the bilayer and floating - bio adhesive tablets 
of rosiglitazone maleate. HPMC was used for the sustained release layer and Sodium 
bicarbonate was used for the floating layer. The floating ability was studied by gamma 
scintigraphy. The release of rosiglitazone maleate from the tablets followed the matrix 
first-order release model. The tablet was buoyant for up to 8 h in the human stomach. 
 
 Multak S et.al,,., 28 (2007) prepared the once daily sustained release tablets of 
aceclofenac by direct compression method using HPMC K4M as polymer. Here, the 
solubility studies of aceclofenac were conducted to select suitable dissolution media.  The 
drug excipient mixtures were subjected to preformulation studies. The tablets were 
subjected to physicochemical, in vitro drug release, stability studies, Preclinical (anti-
inflammatory, analgesic, pharmacokinetic and toxicity studies) and clinical 
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pharmacokinetic studies. Based on the preformulation results, microcrystalline cellulose 
(MCC), dicalcium phosphate and spray dried lactose (SDL) were selected as directly 
compressible vehicles.  By comparing the dissolution profiles with the marketed product, 
the tablet containing HPMC (45%) and MCC (30%) along with talc and magnesium 
stearate (1% w/w, each) (Tablet B7) was considered as a better formulation. This tablet 
exhibited almost similar drug release profile in different dissolution media as that of 
marketed tablet. . The composition of this tablet showed almost similar preclinical 
pharmacological activities and clinic pharmaco kinetic profile as that of marketed tablet 
composition.  
 
 Dhake A. S. et.al,,,29 (2005) developed sustained release model drug tablet using HPMC 
in various ratio. The study shows that HPMC is an appropriate polymer that can be used 
as matrix forming agent prolonged the release of the drug. Preparation of matrices by wet 
granulation was found to be more effective. Release of drug from the matrices can be 
adjusted by using release enhancer like lactose and sodium starch glycollate. Drug with 
HPMC k4m and HPMC E-5 in various proportions like (1:6, 1:5, 1:4) shows the drug 
release sustained at the rate of 33 mg/hr. 
 
 
 Hiremath S. N. et.al,,30 (2007) developed sustained release matrix tablet of Metformin 
Hcl using hydrophilic swellable polymer HPMC with lactose. Three different grade of 
polymer HPMC K4m, HPMC K100m, HPMC K15m, were used in three different ratios 
(2:1, 4:1, and 6:1) to retard the drug release from the matrices. Among the three grade of 
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polymer the tablet prepared with lower viscosity grade (HPMC K4m) shown slightly 
greater drug release than the higher viscosity grade polymer (HPMC K100, HPMC 
K15m). So the drug with HPMC K4m ratio of 6:1 shows promising results and released 
more than 90% drug in 12 hrs. 
 M. Rajesh et.al,, (2010) 31 were prepared using a hydrophilic polymer Hydroxypropyl 
methylcellulose K100M (HPMC K100M) with three concentrations (Drug: polymers 
1:0.5, 1:0.75 and 1:1) by wet granulation method. Invitro release studies revealed that 
famotidine formulation with high proportion of HPMC K100M (1:1) was able to sustain 
the drug release for 10 hours (84.1% ±1.85). Fitting the invitro drug release data to 
kinetic analysis, all the formulations followed the mechanism of both diffusion and 
erosion. All the formulations were stored at 45º±2 ºC, 75 ± 5%RH and subjected to 
stability studies upto 45 days. It showed that all the formulations are physically and 
chemically stable. 
 Ajay Kumar et.al,, (2013)32 were prepared with polymers like HPMC K4M and HPMC 
K100M using directly compression technique. The floating tablets were evaluated for 
uniformity of weight, hardness, friability, drug content, In vitro buoyancy and dissolution 
studies All the prepared batches showed good In vitro buoyancy. The tablet remained 
buoyant for 6-10 hours. The tablets with HPMC K100M were found to float for longer 
duration as compared with formulations containing HPMC K4M. The In vitro dissolution 
studies confirmed the sustained and non fickian drug release from tablets. Stability 
studies showed that tablets can be stored at room temperature. 
 Angilicam Avinash et.al,, (2015)33 were designed floating tablets to study the influence 
of different polymers on its release rate. Nine formulations of famotidine containing 
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varying concentrations of polymers (HPMC E15, HPMC K4M and sodium alginate) were 
designed The floating matrix tablets of famotidine were prepared by direct compression 
method. The powder blend was evaluated for angle of repose, bulk density, tapped 
density, bulkiness, compressibility index and Hausner’s ratio; all these values are within 
the specified limit which indicates good flow properties. The prepared tablets were 
evaluated for physicochemical parameters such as weight variation, hardness, friability, 
floating properties (floating lag time, floating time) and drug content. In vitro release 
studies revealed that out of 9 formulations, formulation F8 was found to be optimized 
which showed sustain the drug release of 97.11% for 10 hours. 
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3. AIM AND OBJECTIVE OF PRESENT STUDY 
 
 To design and develop a stable solid oral dosage form of bilayered tablet of aceclofenac 
with the famotidine in a fixed dose combination to treat Zollinger-Ellison syndrome. 
 
 To select and optimize the concentration of disintegrant for immediate release layer, 
aceclofenac. 
 
 
 To optimize the concentration of Polymer for sustaining layer, famotidine. 
 
 To select the dissolution media, by performing solubility studies. 
 
 
 To evaluate the formulation parameters like weight variation, hardness, friability, 
disintegration, content uniformity, assay. 
 
 To evaluate the In-vitro studies for the prepared trials of bilayered tablets. 
 
 
 To conduct the accelerated stability studies for the prepared tablets as per ICH guidelines 
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3.1 PLAN OF WORK 
The present work was aimed to carryout for the formulation and evaluation of aceclofenac and 
famotidine tablets for floating drug delivery system by using polymers such as microcrystalline 
cellulose, crosspovidone, sodium starch glycolate, lactose, croscarmellose sodium, magnesium 
stearate, and talc.  
This work consists of four steps. 
Step 1 
 Literature survey  
 Selection and collection of drug & raw materials. 
Step 2     
 Drug-polymer compatibility study by FTIR&DSC. 
 Preparation of granules. 
 Evaluation of micromeritic properties of granules.        
 Angle of repose 
 Bulk density 
 Tapped density 
 Carr’s index 
 Hausner’s ratio 
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Step 3 
 Formulation of bilayer floating tablets containing aceclofenac and famotidine drugs. 
 Formulation of immediate release (IR) tablets by direct compression. 
 Formulation of sustain release(SR) tablets by wet granulation.  
Step 4 
Evaluation of prepared tablets 
 Evaluation of  prepared Immediate Release tablets 
  Physical appearance 
 Weight variation 
 Thickness 
 Hardness 
 Friability 
 Wetting time 
 Disintegration 
 Dissolution 
 Evaluation of Sustained Release tablets. 
 Physical appearance 
 Weight variation 
 Friability 
 Dissolution 
 Swelling index 
 Release kinetics 
 Stability studies    
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4.DRUGS AND POLYMER PROFILE 
4.1 ACECLOFENAC 34 
Chemical structure 
 
Fig 4.1. Structure of Aceclofenac 
IUPAC name   
 2-[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxyacetic acid              
Chemical formula 
C16H13Cl2NO4 
Molecular weight            
354.18 
Description  
Aceclofenac is a white to off-white, odourless crystalline powder 
Solubility 
Practically insoluble in water, freely soluble in acetone, soluble in alcohol 
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Melting point         
  149-153 ºC.              
pka value                          
4.7 
Mechanism of action 
Aceclofenac has higher anti-inflammatory action than conventional NSAIDs. It is a cytokine 
inhibitor. Aceclofenac works by blocking the action of a substance in the body called cyclo-
oxygenase. Cyclo-oxygenase is involved in the production of prostaglandins (chemicals in the 
body) which cause pain, swelling and inflammation. Aceclofenac is the glycolic acid ester of 
diclofenac. 
Pharmacokinetics data of aceclofenac 
Oral availability 
 
100% 
Bound in plasma 99% 
Urinary excretion 70-80% 
Volume of distribution 25 -30 L/kg 
 
Half life 3-4 hrs 
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Side effects 
 Gastro intestinal toxicity including abdominal pain, constipation, diarrhoea, dyspepsia, 
flatulence, gross bleeding (perforation, heart burn, nausea, GI ulcers, vomiting). 
 Other events including  – abnormal renal function,  anemia, dizziness,  oedema, elevated 
liver enzymes, headaches, increased bleeding time, pruritis and rashes. 
Drug/Drug Interactions 
Aceclofenac may increase plasma concentrations of lithium, digoxin and methotrexate, increase 
the activity of anticoagulant, inhibits the activity of diuretics, enhance cyclosporin nephrotoxicity 
and precipitate convulsions when co-administered with quinolone antibiotics. Furthermore, hypo 
or hyperglycemia may result from the concomitant administration of aceclofenac and ant diabetic 
drugs, although this is rare. The co administration of aceclofenac with other NSAIDS of 
corticosteroids may results in increased frequency of adverse event. 
 
Drug/Food Interactions 
Aceclofenac is rapidly and completely absorbed after oral administration, peak plasma 
concentrations are reached 1 to 3 hours after an oral dose. The drug is highly protein bound 
(7.99%). The presence of food does alter the extent of absorption of aceclofenac but the 
absorption rate is reduced. The plasma concentration of aceclofenac was approximately twice 
that in synovial fluid after multiple doses of the drug in-patient with knee pain and synovial fluid 
effusion. Aceclofenac is metabolized to a major metabolite, 4'-hydroxyaceclofenac and to a 
number of other metabolites including 5-hydroxyaceclofenac, 4'-hydroxydiclofenac, diclofenac 
and 5-hydroxydiclofenac. Renal excretion is the main route of elimination of aceclofenac with 70 
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to 80% of an administered dose found in the urine, mainly as the glucuronides of aceclofenac 
and its metabolites of each dose of aceclofenac, 20% is excreted in the faeces. The plasma 
elimination half-life of the drug is approximately 4 hours. 
Uses 
It is an analgesic and anti-inflammatory properties, aceclofenac provides symptomatic relief in a 
variety of painful conditions. Aceclofenac reduces joint inflammation, pain intensity and the 
duration of morning stiffness in patients with rheumatoid arthritis, and is similar in efficacy to 
ketoprofen, diclofenac, indomethacin and tenoxicam in these patients. Aceclofenac is also 
effective in other painful conditions (e.g. dental and gynaecological). In contrast to some other 
NSAIDs, aceclofenac has shown stimulatory effects on cartilage matrix synthesis. Aceclofenac is 
well tolerated, with most adverse events being minor and reversible, and affecting mainly the GI 
system.  
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4.2 FAMOTIDINE 35 
Chemical structure 
 
 
Fig 4.2 Structure of famotidine 
IUPAC name      
3-([2-(diaminomethyleneamino)thiazol- 4-yl]methylthio)- N'-
sulfamoylpropanimidamide.                 
Chemical formula       
C8H15N7O2S3       
Molecular weight                  
337.43.          
Description  
Famotidine is a white to pale yellow crystalline compound  
Solubility     
Famotidine is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly 
soluble in water, and practically insoluble in ethanol. 
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Melting point    
163.5 °C                   
pka value           
 9.29                
Mechanism of action/Effect 
Famotidine binds competitively to H2-receptors located on the basolateral membrane of the 
parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and 
nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric 
acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. 
Pharmacokinetics of famotidine 
Oral availability Ranges from 40 to 50%, 
Bound in plasma 15 to 22% 
Urinary excretion Approximately 65-80% of an 
IV dose is excreted 
unchanged  
Volume of distribution 1.0 to 1.3 L/kg 
Half life 2 to 4 hrs 
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Side effects 
Side-effects are associated with famotidine use. In clinical trials, the most common adverse 
effects were headache, dizziness, and constipation or diarrhea. Antacid preparations such as 
famotidine, by suppressing acid-mediated breakdown of proteins, lead to an elevated risk of 
developing food or drug allergies. This happens due to undigested proteins then passing into the 
gastrointestinal tract where sensitization occurs. It is unclear whether this risk occurs with only 
long-term use or with short-term use as well.  
Drug/Drug Interactions 
Famotidine, like other drugs that reduce stomach acid, may interfere with the absorption of drugs 
that require acid for adequate absorption. Examples include iron salts (for example iron 
sulphate), itraconazole (Sporanox), and ketoconazole (Nizoral, Extina, Xolegel, Kuric). 
Dosage and administration    
Duodenal Ulcer 
Acute Therapy: The recommended adult oral dosage for active duodenal ulcer is 40 mg once a 
day at bedtime. Most patients heal within 4 weeks; there is rarely reason to use famotidine at full 
dosage for longer than 6 to 8 weeks. A regimen of 20 mg b.i.d. is also effective. 
Maintenance Therapy: The recommended adult oral dose is 20 mg once a day at bedtime. 
Benign Gastric Ulcer 
Acute Therapy: The recommended adult oral dosage for active benign gastric ulcer is 40 mg 
once a day at bedtime. 
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Gastroesophageal Reflux Disease (GERD): The recommended oral dosage for treatment of adult 
patients with symptoms of GERD is 20 mg b.i.d. for up to 6 weeks. The recommended oral 
dosage for the treatment of adult patients with esophagitis including erosions and ulcerations and 
accompanying symptoms due to GERD is 20 or 40 mg b.i.d. for up to 12 weeks  
 
Drug/Food Interactions 
 Avoid alcohol. 
 Limit caffeine intake. 
 Take without regard to meals, food may slightly increase the product's bioavailability. 
Storage: It should be stored in well closed, light resistant container. 
Uses 
Famotidine is used to treat ulcers of the stomach or intestines. It may be used to prevent 
intestinal ulcers from returning after treatment. This medication is also used to treat certain 
stomach and throat problems caused by too much acid 
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4.3 POLYMER PROFILE 
4.3.1 Microcrystalline cellulose 36 
Synonyms 
 Potato starch, Wheat starch, Corn starch, Rice starch, Cornstarch, Starch, potato, Clearjel, 
Supertah, Keestar, Maizena, Maranta, Melojel, Starch, wheat, Starken, Amylum, Genvis, 
Meluna, Trogum, Starch, corn, Amyla  
 
Chemical Structure 
 
 
 
                                   Fig 4.3. Structure of Micro crystalline cellulose 
 
IUPAC Name         
 5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-
(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-2-[4,5-dihydroxy-2-(hydroxymethyl)-6-
methyloxan-3-yl]oxyoxane-3,4-diol  
 
Molecular Formula       
                   
                     C27H48O20 
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Molecular Weight        
       
                     692.658020 [g/mol] 
Description  
                    Microcrystalline cellulose is refined wood pulp. It is a white, free-flowing powder.  
Solublity 
 The products do not dissolve in water, dilute acid and common organic solvent. They partly 
dissolve in dilute alkali and swell in it. 
Incompatibilities 
 It has been reported that the degradation rate of enalapril maleate was accelerated by in the 
presence of MCC. The MCC appeared to reduce the apparent heat of fusion of the enalapril 
maleate.  
Isosorbide mononitrate, a nitrooxy dioxabicyclic compound used for treatment of angina pectoris 
showed an interaction with cellulose acetate and MCC as evidenced by DSC, IST and HPLC 
studies. 
 
Packing and Storage  
The products are packed in composite paper sacks lined with polyethylene film bag. The net 
weight is 10kg or 25kg per sack. The products shall be stored in sealed container and kept in 
cool, dark and drying place. 
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Applications  
Microcrystalline cellulose is a commonly used excipient in the pharmaceutical industry.It has 
excellent compressibility properties and is used in solid dose forms, such as tablets. Tablets can 
be formed that are hard, but dissolve quickly. Microcrystalline cellulose is the same as cellulose, 
except that it meets USP standards.It is also found as stabilizer, texture modifier, or suspending 
agent among other uses.  
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4.3.2 Cross Povidone37 
 
Synonyms  
 E1201,Kollidon,Plasdone,poly[1-(2-oxo-1-pyrrolidinyl)ethylene],polyvidone,polyvinyl 
pyrrolidone, 1-vinyl-2-pyrrolidinone polymer.  
 
Chemical structure 
 
Fig 4.4. Structure of Povidone  
 
IUPAC Name              
                    1-Ethenyl-2-pyrrolidone  
 
Empirical Formula     
                  (C6H9NO) n 
Molecular Weight       
                 2500 to 3000. 
 
Description                
Povidine occurs as a fine, white to creamy-white colored, odorless or almost odorless, 
hygroscopic powder. 
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Solubility                        
Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol and water; practically 
insoluble in ether, hydrocarbons, and mineral oil. In water, the concentration of a solution is 
limited only by the viscosity of the resulting solution, which is a function of the K-value. 
 
Functional Category   
                    Disintegrant; dissolution aid; suspending agent ; tablet binder.  
 
Incompatibilities         
Pharmaceutical Excipients 2215 Povidone is compatible in solution with a wide range of 
inorganic salts, natural and synthetic resins, and other chemicals. It forms molecular adducts in 
solution with sulfathiazole, sodium salicylate, salicylic acid, Phenobarbital, tannin and other 
compounds . The efficacy of some preservatives e.g. thimerosal, may be adversely affected by 
the formation of complexes with povidone.  
 
Stability and Storage conditions  
 Povidone darkens to some extent on heating at 150oC, with a reduction in aqueous solubility. It 
is stable to a short cycle of heat exposure around 110-130o C; steam sterilization of an aqueous 
solution does not alter its properties.  Aqueous solutions are susceptible to mold growth and 
consequently require the addition of suitable preservatives.  Povidone may be stored under 
ordinary conditions without undergoing decomposition or degradation. However, since the 
powder is hydroscopic, it should be stored in an airtight container in a cool, dry place.  
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Applications  
Although povidone is used in a variety of pharmaceutical formulations, it is primarily used in 
solid-dosage forms. In tableting, povidone solutions are used as binders in wet-granulation 
process. 2,3 Povidone is also added to powder blends in the dry form and granulated in situ by 
the addition of water, alcohol, or hydroalcoholic solutions.Povidone is used as a Solubilizer in 
oral and parenteral formulations and has been shown to enhance dissolution of poorly soluble 
drugs from solid-dosage forms. 4-6 Povidone solutions may also be used as coating agents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PADMAVATHI COLLEGE OF PHARMACY-DPI Page 42 
 
4.3.3 Sodium Starch Glycolate38 
 
Synonyms 
Carboxymethyl starch sodium salt; carboxymethylamylum natricum; Explosol; Explotab; 
Glycolys; Primojel; starch carboxymethyl  ether, sodium salt; Tablo; Vivastar P. 
                                      
Chemical Structure 
                                
                                   
                               Fig 4.5. Structure of Sodium Starch Glycolate 
 
IUPAC name       
(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-
(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol  
 
Molecular Formula            
                     C12H22O11 
 
Molecular Weight              
                    342.296480 [g/mol] 
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Description                       
                    It is a white to off-white, tasteless, odorless, relatively free flowing  powder. 
Solubility 
                   It is very hygroscopic,in water it gives a translucent suspension ,insoluble in organic 
solvents. 
Incompatibilities     
Sodium starch glycolate is incompatible with ‘clenbuterol’ which is a                                                    
bronchodilator. 
 
Packaging and storage 
Preserve in well-closed containers,preferably protected from wide variations in temperature and 
humidity,which may cause caking.  
Applications 
Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in capsule and 
tablet formulations.It is recommended to use in tablets prepared by either direct-compression or 
wet-granulation process. 
              The recommended concentration in a formulation is 2-8% with the optimum 
concentration about 4% although in many cases 2% is sufficient .Disintegration occurs by rapid 
and enormous swelling. 
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4.3.4 Lactose39  
Synonyms 
Anhydrous Lactose NF 60 M ; Anhydrous Lactose NF Direct Tab letting ; Lacto press 
Anhydrous; Lactosum; Milk Sugar ; Pharmatose DCL-21; Pharmatose DCL-22; Saccharum 
Latis; Super-tab Anhydrous.  
 
Chemical structure    
 
 
 
 
 
 
 
 
       
                              Fig 4.6. Structure of anhydrous α and β lactose 
 
IUPAC name                  
                    O-β-D-galacto pyranosyl-(1,4)-β-D-gluco pyranose  
 
Molecular formula         
                   C12H22011 
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Molecular weight           
                  342.30. 
 
Description                  
                  Lactose occurs as a white to off-white crystalline particles or powder.                 
Solubility                            
                    Soluble in water, sparingly soluble in ethanol and ether.  
Functional category    
Binding agents ; directly compression vehicle; Lyophilization aid; tablet and capsule filler.  
 
Incompatibilities 
Lactose is incompatible with strong oxidizers. When mixtures containing a hydrophobic 
Leukotrienes antagonist and hydrous lactose were stored for 6 weeks at 40oc and 75% RH, 
mixture containing anhydrous lactose showed greater moisture uptake and drug degradation.  
 
Stability and storage conditions  
 Lactose may develop a brown coloration on storage, the reaction accelerated by warm, damp 
conditions. At 80% RH and 80oc tablets containing anhydrous lactose have been shown to 
expand 1.2 times after one day. It should be stored in a well-closed container in a cool, dry place.  
 
Applications  
 Anhydrous lactose is widely used in direct compression vehicle in tablet. It can also be used 
with the moisture-sensitive drugs due to its low-moisture content.  
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4.3.5 Croscarmellose Sodium40 
Synonyms 
 Ac-Di-Sol; crosslinked carboxymethylcellulose sodium, Explocel; modified cellulose gum; 
Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol.  
 
Chemical structure 
 
 
 
 
 
 
 
 
 
 
                          Fig 4.7  Structure of Croscarmellose Sodium 
IUPAC Name           
                      Acetic acid,2,3,4,5,6-pentahydroxy hexanal  
Empirical Formula  
                      NaC6H7O6 
Molecular Weight    
                      198 
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Description         
                     Croscarmellose sodium occurs as an odorless, white or grayish-white powder. 
 
Solubility  
Insoluble in water, although croscarmellose sodium rapidly swells to 4-8 times its original 
volume on contact with water. Practically insoluble in acetone, ethanol and toluene.   
 
Functional Category      
                  Tablet and capsule disintegrant  
 
Incompatibilities  
The efficacy of disintegrates, such as croscarmellose sodium, may be slightly reduced in tablet 
formulations prepared by either the wet-granulation or direct-compression process that contain 
hygroscopic excipients such as sorbitol. Croscarmellose sodium is not compatible with strong 
acids or with soluble salts of iron and some other metals such as aluminum, mercury and zinc.      
 
Stability and Storage Conditions 
Croscarmellose sodium is a stable though hygroscopic material.  A model tablet formulation 
prepared by direct compression, with croscarmellose sodium as a disintegrant, showed no 
significant difference in drug dissolution after storage at 30oC for 14 months. Croscarmellose 
sodium should be stored in a well-closed container in a cool, dry place.  
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Application in Pharmaceutical Formulation or Technology 
In tablet formulations, croscarmellose sodium may be used in both direct-compression and wet-
granulation processes. When used in wet granulations, the croscarmellose sodium should be 
added in both the wet and dry stages of the process (intra-and extragranularly) so that the 
wicking and swelling ability of the disintegrate is best utilized.Croscarmellose sodium at 
concentrations up to 5% w/w may be used as a tablet disintegrant, although normally 2%w/w is 
used in tablets prepared by direct compression and 3% w/w in tablets prepared by a wet-
granulation process.  
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4.3.6 Magnesium Stearate41 
Synonyms 
Dibasic magnesium stearate, magnesium distearate, magnesium octadecanoate, octadecanoic 
acid, magnesium salt, stearic acid. 
 
Chemical structure 
 
 
 
 
 
 
 
                                   Fig 4.8.Structure of Magnesium Stearate 
IUPAC name                
                          Magnesium octadecanoate                   
Chemical Formula       
                     C36H70MgO4 
Molecular weight         
                    591.24 
Description   
                    It occurs as a white to off-white  powder and odourless. 
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Solubility  
It is not soluble in water .Practically insoluble in ethanol, ether and water, slightly soluble 
in warm benzene and warm ethanol (95%). 
 
Functional category     
                   It is used as diluent and lubricating agent. 
Incompatabilities 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin, some 
vitamins, and most alkaloidal salts.  
 
Stability and storage conditions 
Magnesium stearate is stable and should be stored in a well-closed container in a cool, dry place.  
 
Applications  
Magnesium stearate is often used a diluent  in the manufacture of medical tablets, capsules and 
powder. In this regard, the substance is also useful, because it has lubricating properties, 
preventing ingredients from sticking to manufacturing equipment during the compression of 
chemical powders into solid tablets.  
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5. METHODOLOGY 
Table 5.1 List of chemicals used in this present work 
Chemicals Source/manufacturer 
Aceclofenac 
Famotidine 
HPMC K4M 
MCC 
PVP-K30 
Isopropyl Alcohol 
Talc 
Magnesium Stearate 
Starch 
Lactose 
Crosscarmellose sodium 
Sodium starch glycolate 
Madras Pharmaceuticals Ltd, Chennai  
Madras Pharmaceuticals Ltd, Chennai  
Drugs India, Hyderabad 
Drugs India, Hyderabad 
Drugs India, Hyderabad 
SDFCL , Mumbai  
SDFCL , Mumbai  
SDFCL , Mumbai  
SDFCL , Mumbai  
SDFCL , Mumbai  
SDFCL , Mumbai  
SDFCL , Mumbai  
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Table 5.2 List of instruments/equipments used. 
Equipments Modified/Manufacturer 
Electronic balance 
 
Double rotary tablet compression 
machine 
Hardness tester, Pfizer 
 
Friabilator 
pH meter 
Hot air oven 
 
Dissolution Apparatus 
 
Double beam spectrophotometer 
 
FT-IR Spectrophotometer 
Differential Scanning Colorimeter 
Wensar weighing scales Ltd, 
Mod.No:PGB200 
Karunavati Pvt Ltd., Rajasthan (RIMEK 
minipress) 
Mitutoyo South Asia Pvt Ltd., New 
Delhi 
Roche Friabilator 
Shankar Scientific, Chennai 
Model MP-1 Plus Susima Dharma 
 
Lab india disso-2000 
Schimadzu 1700 UV-Vis Double beam 
spectrophotometer,Shimadzu Scientific 
Instruments, Japan 
Shimadzu Scientific Instruments, Japan 
Q10 TA systems, USA 
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5.1 Construction of calibration curve for Aceclofenac and Famotidine 
5.1.1 Stock for standard curve  
Accurately weighed 100mg of aceclofenac in 100 mL of volumetric flask was dissolved 
completely with1/ 3 volume of pH 7.4 phosphate buffer and volume made up with the same. 
From above stock solution 1mL was taken into 100mL volumetric flask and diluted with pH 7.4 
phosphate buffer in order to get 5, 10, 15 & 20µg/ mL concentration and absorbance was read at 
273nm. 
The same method was adopted for the construction of calibration curve of famotidine and  
absorbance was at 260 nm. 
 
5.2 Preformulation studies 
Preformulation can be defined as an investigation of physical and chemical properties of drug 
substance alone and when combined with excipients. The overall objective of Preformulation 
testing is to generate information useful to the formulator in developing stable and bioavailable 
dosage forms that can be mass produced. The following data must be considered, 
 Loss on drying 
 Solubility studies 
 Micromeritic properties  
 pH studies 
 Compatibility studies 
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5.2.1 Loss on drying studies 
The Loss on Drying Test is designed to measure the amount of water and volatile matters in a 
sample when the sample is dried under specified conditions. Dry a weighing bottle for about 30 
minutes under 100-1050c, allow to cool it in a desiccators if heated, and weigh it accurately. 
Place 1 to 2g of acclofenac into the weighing bottle spread the sample so that the layer is not 
thicker than 5mm, and weighs it accurately. Place the bottle in the drying oven, remove the 
stopper (placing it nearby), dry under 1050c for 3 hours, stopper again, take the bottle out of the 
oven, and weigh it again. Allow to cool it in a desiccator, and weigh it accurately. Same 
procedure was also done with famotidine as a sample. 
 
      Initial weight – Final weight 
LOD (%) = --------------------------------------- X 100 
Initial weight 
 
 
5.2.2 Solubility studies of aceclofenac drug and famotidine drug  
An excess quantity of aceclofenac drug and famotidine drugs were taken separately and added in 
10ml of different solutions. These solutions were shaken well for few minutes. Then the 
solubility was observed. 
5.2.3 Micromeritic properties evaluation 
Angle of repose of aceclofenac and famotidine were assessed by the fixed funnel method. A 
known amount of drug was allowed to flow through a funnel fixed at a constant height (h) and 
the height and diameter (2r) of the pile of powder were measured to calculate the angle of repose 
as θ= tan-1 (h/r). The loose bulk density (LBD) and tapped bulk density (TBD) of aceclofenac 
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and famotidine were determined using a bulk density test apparatus. Carr’s index and Hausner’s 
ratios were calculated using LBD and TBD values. Then again the micromeritic properties of 
these two drugs were checked with the addition of various fillers. 
5. 2.3.1 Flow Properties42-45 
 5. 2.3.1.1 Angle of repose (θ) 
It is a direct measure of flow property of powders. It is the maximum angle that can be obtained 
between the free standing surface of a powder heap and the horizontal. 
Procedure 
Angle of repose was determined using funnel method. Pour the powder on to the surface of 
funnel from certain height(h) . Circumference was drawn with a pencil on the graph paper and 
the radius of base of a pile was measured at 5 different points and average was taken as 
radius(r).By using this  Angle of repose was calculated using following formula: 
                                             Angle of repose(θ)=tan-1(h/r) 
Where, 
                 h = height of a pile  
                 r = radius of pile base. 
Acceptable range for angle of repose is 20θ to 40θ. 
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5. 2.3.1.2 Bulk density 
It is the ratio of given mass of powder and its bulk volume determined by measuring the volume 
of known mass of powder sample that has been passed through the screen in to graduating 
cylinder. 
Bulk density was determined according to USP method I. The powder sample under test was 
screened through sieve no 18 and 10 mg of pure drug was accurately weighed and filled in a 
100ml graduated cylinder and the powder was leveled and the unsettled volume (Vo) was noted. 
Bulk density (Db) was calculated in g/ml by the formula:       
                                                                 Db= M/Vo                              
Where, 
                M = mass of powder taken 
                Vo= unsettled apparent volume 
Limits 
It has been stated that the bulk density values having less than 1.2 g/cm3 indicates good packing 
and values greater than 1.5 g/cm3 indicates poor packing.  
 
5. 2.3.1.3. Tapped density 
Tapped density was determined by USP method II. The powder sample under test was screened 
through sieve no.18 and 10 mg of pure drug was filled in 100ml graduated cylinder of tap density 
tester (electrolab, ETD 1020). The mechanical tapping of the cylinder was carried out using 
tapped density tester at a normal rate of 250 drops per minute for 500 times initially and the 
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initial tapped volume (Va) was noted. Tapping was proceeded further for additional 750 times 
and volume was noted. The difference between two tapping volumes was calculated. Tapping 
was continued for additional 1250 tap if the difference is more than 2%. This volume was noted 
as, the final tapped volume (Vo). The tapped density (Dt) was calculated in g/ml by the formula: 
Dt = M/ Vo 
                                       Where, 
M = Weight of sample powder 
                                                   Vo = final tapped volume 
 
5. 2.3.1.4. Carr’s index                      
Compressibility index of the powder blend was determined by Carr’s compressibility index. It is 
a simple test to evaluate the bulk density and tapped density of a powder and the rate at which it 
packed down.  
The formula for Carr’s index is as below equation 
 
                     Tapped density – Bulk density 
                       Carr’s index =   ------------------------------------------   × 100 
                                                                 Tapped Density 
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Tab 5.3 Compressibility index 
 
 
 
 
 
 
 
 
5. 2.3.1.5. Compressibility Index (% Compressibility) 
Carr’s compressibility index i.e., % compressibility indicates the flow property and packing 
ability of the tablet. It is determined by measuring both the bulk and tapped density of a powder. 
When the % compressibility ranges from 5 to 16, the materials have acceptable flow property 
and packing ability. Compressibility Index was calculated using following equation: 
                                     
                                      CI (%) = [(Dt -Db)/Dt] x100 
   Where, 
                 Dt =  Tapped density        
                 Db =  Bulk density 
% Compressibility Flow ability 
5-15 Excellent 
12-16 Good 
18-21 Fair- Possible 
23-35 Poor 
33-38 Very poor 
<40 Very, Very poor 
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5. 2.3.1.6. Hausner’s Ratio 
The Hausner ratio indicates the flowability and packing ability of the tablet. When the Hausner 
ratio is close to 1, materials have acceptable flow and packing ability. Hausner Ratio was 
calculated using the formula: 
                                                Hausner Ratio = Dt/Db 
Where, 
                Dt = tapped density 
                Db = bulk density    
Tab 5.4. Standard limits corresponding to powder flow and packaging characteristics 
 
 
 
 
 
 
 
 
Angle of 
repose(θ) 
Compressibility    
Index (%) 
Hausner’s ratio Flow properties 
25-30 <10 1.00-1.11 Excellent 
31-35 11-15 1.12-1.18 Good 
36-40 16-20 1.19-1.25 Fair 
41-45 21-25 1.26-1.34 Passable 
46-55 26-31 1.35-1.45 Poor 
56-65 32-37 1.46-1.59 Very poor 
> 66 >38 >1.6 Very very poor 
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5.2.4 pH Studies 
The pH studies were done for both aceclofenac and famotidine which were dissolved in their 
suitable solvent, determined with the help of pH potentiometer 
5.2.5 Compatibility studies  
5.2.5.1. FT-IR Study 
Infra red spectra matching approach was used for the detection of any possible chemical reaction 
between the drug and the excipients. A physical mixture (1:1) of drug and polymer was prepared 
and mixed with suitable quantity of potassium bromide. About 100mg of this mixture was 
compressed to form a transparent pellet using a hydraulic press at 10 tons pressure. It was 
scanned from 4000 to 400 cm-1 in a shimadzu FT-IR spectrophotometer. The IR spectrum of the 
physical mixture was compared with those of pure drug and excipients and matching was done to 
detect any appearance or disappearance of peaks. 
5.2.5.2. Differential scanning Calorimetry (DSC) 
DSC thermo grams of drug and excipients were recorded using a differential scanning 
calorimeter (Q10 TA systems, USA). About 5mg of sample were crimped in a standard 
aluminium pan and heated in a temperature range of 500C to 4500C at a heating rate of 100C per 
minute in nitrogen atmosphere. 
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5.3 FORMULATION OF BILAYERED FLOATING TABLETS 
5.3.1 Formulation of immediate release (IR) tablets by direct compression 
The inner core tablets were prepared by using direct compression method as per formulation 
variable shown in Tab5.5. Powder mixtures of aceclofenac, microcrystalline cellulose (MCC, 
Avicel  PH-102), cross-carmellose sodium (Ac-Di-Sol), Sodium starch glycolate, crospovidone, 
lactose monohydrate  ingredients were dry blended for  20  min  followed by addition of magnesium 
stearate. The mixtures were then further blended for 10 min. 181 mg of resultant powder blend 
was manually compressed using hydraulic press at a pressure of 1 ton, with a 9mm punch and die to 
obtain the core tablet. 
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Tab.5.5 Composition of various formulations of immediate release layer 
Compositions 
 
                                            Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 
Aceclofenac(mg) 100 100  100 100 100  100 100 100  
Cross 
povidone(mg) 
5     7.5  12.5   
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
MCC(mg)  
- 
 
 
- 
 
 
- 
 
5     7.5  12.5   
- 
 
 
- 
 
Sodium starch 
glycolate. (mg) 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
5     7.5  
Lactose.(mg) 68.5 66.0  61  68.5 66.0  61 68.5 66.0  
Purified 
talc.(mg) 
5 5  5  5 5  5  5 5  
Magnesium 
stereate(mg) 
2.5 2.5  2.5  2.5 2.5  2.5  2.5 2.5  
 
5.3.2 Preparation of bi-layered floating tablets (wet granulation) 
Bilayered tablet of sustained release famotidine and immediate release aceclofenac were 
prepared through wet granulation method according to the composition. Various steps (sieving, 
dry mixing, binder solution preparation, granulation and subsequent drying)were involved in wet 
granulation process. 
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Wet granulation Procedure 
Granulation of famotidine 
Step:1 
 Sieving 
The active ingredient Famotidine drug was passed through the sieve#40 followed by the other 
ingredients were passed the same sieve. 
Step:2 
 Dry mixing 
              Famotidine, HPMC K100M, HPMC K4M, MCC were taken in a poly bag and 
mixed for 5minutes to ensure uniform mixing of the ingredients with the drug. 
Step:3 
 Preparation of binder solution 
 PVP-K30  
 IPA 
              Weigh 9mg of PVP K-30 accurately and it is mixed with IPA to form a paste is 
used as binder solution and kept separately. 
Step:4 
 Granulation 
              The binder solution was added slowly to the dry mixed ingredients with constant 
mixing till to get solid mass to form uniform and optimum granules. 
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Step:5 
 Drying 
              Then the wet granules were dried in trays and pass the air for drying since the IPA 
is corrosive and also get evaporated quickly. So air drying is only suitable for drying, samples 
were removed randomly at different time intervals from the total bulk of the granules and then 
checked out for moisture content. 
Step:6 
 Sieving 
              The dried materials were passed through the sieve #20 
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Tab.5.6 Composition of various formulations of sustained release layer 
 
compositions 
     Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 
Famotidine (mg)      40      40  40  40       40      40  40  40 
HPMC(mg) 87.5  105 122.5 140 - -      - - 
Guar gum(mg) - - - - 87.5  105 122.5 140 
NaHC03(mg) 70 70 70 70 70 70 70 70 
PVP(mg) 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 
Lactose 
monohydrate(mg) 
131.5  114 96.5 79 96.5 61.5 44 26.5 
Magnesium 
stearate(mg) 
3.5  3.5 3.5 3.5 3.5  3.5 3.5 3.5 
IPA q.s. q.s. q.s q.s. q.s. q.s. q.s q.s. 
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5.3.3 Lubrication and compression of bilayered tablets 
Magnesium stearate, and talc were weighed and they were passed through sieve#20.Then mixed 
with dried granules of Famotidine in a polybag for 5minutes to get a uniform blend. Then the 
lubricated granules of Famotidine and lubricated granules of Aceclofenac drug were added in the 
separate hopper in double rotary punching machine and compressed into bilayered tablets using 
18.6 X 9mm caplet shape punches, at weight of 531mg each.  
 
5.4 POST COMPRESSION EVALUATION OF BILAYERED TABLETS   
 
5.4.1 Physical appearance            
The physical appearance of the compressed tablets involves the measurement of a number of 
attributes like tablet shape, smoothness, chipping, cracks, surface texture, colour, embossing, 
debossing. 
 
5.4.2 Weight variation   
Twenty tablets were randomly selected from each batch weighed individually. Calculate the 
average weight and compare the individual weight to the average weight.  
                            Tab 5.7 Specifications for Weight variation of Tablets 
AVERAGE WEIGHT OF 
TABLETS(mg) 
 
% DIFFERENCE 
130 or less 10% 
130 or 324 7.5% 
> 324 5% 
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5.4.3 Thickness   
Five  tablets from each batch of formulation  were  collected  and  the  thicknesses  of  the  tablets  
were measured  with  the  help  of  screw gauge.  The average thickness was calculated. 
 
5.4.4 Hardness  
Hardness was measured by using Monsanto tablet hardness tester. The hardness of five tablets in 
each batch was measured and the average hardness was calculated in terms of kg/cm. 
  
5.4.5 Friability  
In friability testing the tablets are subjected to abrasion and shock. It gives an indication of the 
tablets ability to resist chipping and abrasion during transportation and shipping.  
 If the tablet weight is >650 mg 10 tablets were taken and initial weight was noted. For tablets of 
weight less than 650 mg the number of tablets equivalent to a weight of 6.5 g were taken. The 
tablets were rotated in Roche Friabilator for 100 revolutions at 25 rpm. The tablets were de-
dusted and reweighed. The %friability should be not more than 1% w/w of the tablets is being 
tested.      
 
The % friability is expressed as the loss of weight and is calculated by formula  
 
%F = {(W – W0)/W} x 100 
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Where,  
                               % F  = Friability of tablets in percent.  
                                     W  = Initial Wight of tablets. 
                                    WO  = Final weight of tablets. 
                    
5.4.6 Wetting time   
Wetting time of dosage form is related to the contact angle. A piece of tissue paper folded twice 
was placed in a small petridish containing 6 ml of water. Tablet was kept on the paper and the 
time for complete wetting was measured.  The mean ± SD values were calculated accordingly.  
 
 
5.4.7 Drug content   
For determination of drug content at least five tablets from each formulation were weighed 
individually, crushed and diluted to 100 ml with sufficient amount of phosphate buffer of pH 7.4 
in a volumetric flask. Then aliquot of the filtrate was diluted suitably and analyzed 
spectrophotometrically for each drugs against blank. Drug content was calculated using standard 
curve. 
  
5.4.8 Disintegration time  
Disintegration time is the time required for a tablet to break up into granules of specified size (or 
smaller), under carefully specified test conditions. The disintegration test is carried out in an 
apparatus containing a basket rack assembly with six glass tubes of 7.75 cm length and 2.15 mm 
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in diameter the bottom of which consists of a 10 mesh sieve. The basket is raised and lowered 
28-32 times per minute in the medium of 900 ml which is maintained at 37±2°C. Six tablets were 
placed in each of the tubes and the time required for complete passage of tablet fragments 
through the sieve (# 10) was considered as the disintegration time of the tablet. 
 
5.4.9 Dissolution Studies  
Dissolution is a process by which the disintegrated solid solute enters the solution. The test 
determines the time required for a definite percentage of the drug in a tablet to dissolve under 
specified conditions.  
 
In-vitro release studies for immediate release (IR)  
Dissolution rate studies of both the drugs from all formulations were performed using dissolution 
rate testing apparatus with paddle. The dissolution fluid was 900ml of phosphate buffer pH 7.4. 
The test was performed at a speed of 50rpm and at a temperature of 37±0.5°C. Samples of 
dissolution medium (5ml) were withdrawn through a filter of 0.45μm at different time intervals, 
suitably diluted and assayed for Aceclofenac and Famotidine by measuring absorbance at 273 
nm. The dissolution experiments were conducted in triplicate. 
 
In-vitro Dissolution methods for bilayer floating tablets 
The release of Aceclofenac and Famotidine from the bilayer floating tablet was accomplished In-
vitro release study was carried out (USP dissolution test apparatus Type-II Paddle type) using 
900 ml of Distilled water with 0.5% SLS a. The paddles are rotated at 50 rpm. The medium was 
set at 37 ± 0.50 C. Aliquot (5 ml) of the solution was collected from the dissolution apparatus 
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hourly and was replaced with fresh dissolution medium. The withdrawn samples were analyzed 
by an UV spectrophotometer at 260 nm.  
5.5 Stability studies  
The purpose of stability testing is to provide evidence on how the quality of a drug substance or 
drug product varies with time under the influence of variety of environmental factors such as 
temperature, humidity. Selected formulations were subjected to stability studies as per ICH 
guidelines at 30oC/65% RH and 40oC/75% RH for 45 days. Sample were taken and analyzed at 
time interval.  
Selected formulation were subjected to stability studies as per ICH guidelines sample were taken 
and analysed at time interval of 15 days for 45 days.  
      
 
Tab 5.8.  Storage conditions for checking the quality of drug product 
S.NO STUDY STORAGE CONDITION 
MINIMUM 
TIME PERIOD 
1. Long term 
25oC + 2oC/60% RH + 5oC (or) 
30C + 2oC/65% RH + 5%RH 
 
12 months 
2. Intermediate 30oC + 2oC/65% RH + 5%RH 6 months 
3. Accelerated 40oC + 2oC/75% RH + 5%RH 6 months 
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5.6 KINETIC MODELS 
Release Kinetics   
One of the most important and challenging areas in the drug delivery field is to predict the 
release of the active agent as a function of time using both simple and sophisticated 
mathematical models. The importance of such models lies in their utility during both the design 
stage of a pharmaceutical formulation and the experimental verification of a release mechanism. 
In order to identify a particular release mechanism, experimental data of statistical significance 
are compared to a solution of the theoretical model. It is therefore clear that only a combination 
of accurate and precise data with models accurately depicting the physical situation will provide 
an insight into the actual mechanism of release. 
To analyses the mechanism for the drug release and drug release rate kinetics of the dosage 
form, the data obtained was fitted in to Zero order and First order model. In this by comparing 
the R-values obtained, the best-fit model was selected. 
Zero Order Kinetics 
This model describes the system where the release rate is independent of the concentration of the 
dissolved species. Drug dissolution from pharmaceutical dosage forms that do not disaggregate 
and release the drug slowly assuming that area does not change and no equilibrium conditions 
are obtained can be represented by the following equation. 
                                                              W0-Wt=Kt 
Where, 
            Wo = Initial amount of drug in pharmaceutical dosage form 
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 Wt = Amount of drug in the dosage form at time t 
 K = Proportionality constant. 
Dividing this equation by Wo and simplifying 
ft=kot 
Where, ft = 1-(Wt/Wo) 
            which represents the fraction of drug dissolved in time t  
    Ko= Apparent dissolution rate constant or zero order release constant 
 The pharmaceutical dosage forms following this profile release the same amount of drug 
by unit time and it is the ideal method of drug release in order to achieve a pharmacological 
prolonged action. This following relation can in a simple way express this model. 
Qt = Qo+Kot 
Where, Qt= Amount of drug dissolved in time t,  
Qo = Initial amount of drug in the solution and 
Ko = Zero order release constant. 
First Order Kinetics 
The first order equation describes the release from systems where the dissolution rate is 
dependent upon the concentration of the dissolving species. 
To study the first order release rate kinetics, the release rate data were fitted to the 
following equation. 
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                log Qt = log Qo + K1t / 2.303 
Where, Qt = Amount of drug released in time t, 
Qo = Initial amount of drug in the solution and 
K1 = First order release constant. 
The pharmaceutical dosage forms following this dissolution profile, release the drug in a way 
that is proportional to the amount of drug remaining in its interior, in such a way that the amount 
of drug released by unit of time diminished.  
Higuchi Model 
 
A large number of modified release dosage form contain some sort of matrix system. In such 
instances, the drug dissolves from the matrix. The dissolution pattern of the drug is dictated by  
water penetration rate (diffusion controlled) and thus the following relationship applies as 
formula: 
                                                         Q = k 2 t
1/2 
  
 
 
Where Q is the percent of drug release at time t, and k2  is the diffusion rate constant 
In higuchi model, a plot of % drug released versus square root of time is linear. 
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6. RESULTS AND DISCUSSION  
6.1 Construction of calibration curve for Aceclofenac and Famotidine 
6.1.1Standard curve for aceclofenac in pH 7.4 buffer 
                Tab  6.1 Standard plot of aceclofenac   
 
 
 
 
 
 
               
Fig  6.1 Standard plot of aceclofenac  in pH 7.4 buffer 
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        6.1.2 Calibration curve for famotidine 
                 Table 6.2 Standard plot of famotidine  
 
 
 
 
 
 
 
     
Fig 6.2 Standard plot of famotidine  
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5 0.212 
10 0.424 
15 0.636 
20 0.884 
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6.2 Preformulation Studies  
             Tab 6.3.  Solubility studies of aceclofenac and famotidine  
Solvent Aceclofenac Famotidine 
Water Soluble Soluble 
Methanol Highly Soluble Highly Soluble 
Ethanol Sparingly soluble Sparingly soluble 
Chloroform Insoluble Soluble 
DMSO Soluble Soluble 
0.1N Hcl Soluble Soluble 
pH 6.8 buffer Highly Soluble Soluble 
pH7.4 buffer Soluble Sparingly soluble 
 
The availability of literature on solubility profile of aceclofenac and famotidine indicates that the 
drugs were freely soluble in methanol and water. And also it tells that both drugs solubility 
increases by increasing the pH nearly alkaline. This was confirmed by observing the solubility 
studies of aceclofenac, famotidine hemi hydrate practically. However, pH 6.8 phosphate buffer 
may be suitable for dissolution studies as sufficient solubility was attained at this pH for both the 
drugs. But on the other hand, the present formulation contains sustained release layer and 
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immediate release layer too; it would be more meaningful to use both acidic and alkaline media 
for dissolution studies.  
 
6.3 Micromeritic evaluation 
Tab 6.4 Flow properties of aceclofenac IR layer granules 
Formulation 
code 
Angle of 
repose 
(θ) 
Bulk 
density 
gm/cc 
Tapped 
density 
gm/cc 
Carr’s index 
% 
Hausner’s 
ratio 
% 
F1 21.04± 0.14 0.304± 0.004 0.351± .05 17.0 ± 0.11 1.17 ±0.06 
F2 21.09± 0.08 0.317± 0.002 0.367±0.08 18.1 ± 0.09 1.19 ±0.03 
F3 21.46± 0.15 0.310± 0.007 0.360±0.01 18.7 ± 0.07 1.21 ±0.02 
F4 24.88± 0.13 0.318± 0.007 0.378±.06 19.5 ± 0.05 1.19 ±0.04 
F5 24.23± 0.10 0.294± 0.005 0.346±0.04 19.5 ± 0.10 1.20 ±0.05 
F6 24.09± 0.10 0.307± 0.004 0.360±0.02 20 ± 0.10 1.24 ±0.07 
F7 24.78± 0.12 0.311± 0.04 0.368±0.05 19.1 ± 0.11 1.22 ±0.07 
F8 25.56± 0.18 0.265± 0.06 0.312±0.03 20 ± 0.09 1.23 ±0.02 
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Tab 6.5 Flow properties of famotidine SR layer granules 
Formulation 
code 
Angle of 
repose 
(θ) 
Bulk 
density 
gm/cc 
Tapped 
density 
gm/cc 
Carr’s index 
% 
Hausner’s 
ratio 
% 
F1 21.04± 0.14 0.304± 0.007 0.351± .03 13.41± 0.09 1.15 ±0.05 
F2 21.09± 0.08 0.317± 0.06 0.367±0.05 13.63± 0.05 1.18 ±0.07 
F3 21.46± 0.15 0.310± 0.04 0.360±0.08 13.89± 0.10 1.20 ±0.06 
F4 24088± 0.13 0.318± 0.005 0.378±0.01 15.87± 0.09 1.19 ±0.04 
F5 24.23± 0.10 0.294± 0.004 0.346±0.06 15.02± 0.11 1.22 ±0.05 
F6 24.09± 0.10 0.307± 0.002 0.360±0.04 14.72± 0.07 1.24 ±0.03 
F7 24.78± 0.12 0.311± 0.007 0.368±0.02 15.21± 0.10 1.22 ±0.07 
F8 25.56± 0.18 0.365± 0.06 0.312±0.05 15.06± 0.11 1.24 ±0.02 
 
 
6.4 pH studies 
The pH value of aceclofenac is 7.4. The pH value of famotidine is 6.7 So, both the drugs were 
well soluble in pH 5and 7 and have more unionized nature in this pH. 
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6.5 Compatibility studies 
FT-IR spectroscopy was employed to ascertain the compatibility of drugs with polymers. The 
individual drug and drug with polymers were separately scanned. Both the spectra were 
compared for confirmation of common principal peaks. 3505.03, 3400.28, cm-1 for NH 
stretching of famotidine and peaks at 1598.44 cm-1 wave number were due to C-C stretching in 
aliphatic chain and prominent peaks at 1728 cm-1and 1282-1320 cm-1 were due to C=O 
stretching of aceclofenac.  
Therefore Aceclofenac and famotidine with polymers showed no significant variation in height, 
intensity and position of peaks, suggesting that drug and excipients were compatible. There is no 
interaction between drug and polymer. DSC peaks are observed their  corresponding meting 
points and the same were also shown in formulation, hence it indicates that no interaction of 
drugs and polymers in the formulation. 
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Fig 6.3 FTIR Spectra of bilayer formulation of aceclofenac and famotidine  
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Fig 6.4 DSC thermogram of aceclofenac pure 
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Fig 6.5 DSC thermogram of famotidine pure 
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Fig 6.6 DSC thermogram physical mixture of famotidine and excipients 
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Fig 6.7 DSC of formulation 
 
 
 
PADMAVATHI COLLEGE OF PHARMACY-DPI Page 85 
 
6.6 POST COMPRESSION EVALUATION 
Tab 6.6 Physicochemical evaluations of bi-layered tablets 
Formulation 
Avg. 
Weight(Mea
n ±S.D) 
 
Thickness 
(mm) 
Hardness 
(Kg/cm
2
)
 
Friability 
(% ) 
Drug content 
(% ) 
F1 540.4±0.48 4.5±0.055 2.4±0.32 1.435 98.70 
F2 532.6±0.74 4.7±0.010 6.4±0.29 0.492 99.25 
F3 534.7±0.62 4.1±0.017 6.9±0.24 0.501 99.42 
F4 545.4±0.47 4.3±0.012 2.3±0.41 2.963 97.52 
F5 541.2±0.23 4.5±0.072 6.1±0.32 0.478 98.24 
F6 531.9±0.32 4.9±0.021 6.8±0.32 0.242 98.63 
F7 528.1±0.54 4.7±0.054 5.8±0.39 0.414 98.15 
F8 539.8±0.37 5.0±0.034 6.4±0.42 0.417 99.42 
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6.7 DISSOLUTION  STUDIES 
Tab 6.7 Cumulative percentage of drug release of  famotidine  SR layer for Formulation 
F1-F8 formulated with HPMC and Guar Gum of different concentrations 
TIME 
(hrs) 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
1 36 ±0.3 30±0.56 27±0.24 19±0.44 16±0.24 20±0.64 11±0.54 10±0.25 
2 52±0.33 45±0.34 42±0.34 32±0.54 29±0.22 31±0.24 19±0.61 19±0.84 
3 59±0.45 59±0.75 49±0.15 42±0.24 44±0.55 43±0.29 26±0.54 29±0.94 
4 68±0.52 69±0.25 58±0.55 54±0.35 50±0.14 49±0.34 38±0.34 46±0.56 
5 89±0.23 78±0.32 66±0.25 61±0.21 59±0.85 60±0.21 45±0.61 58±0.75 
6 95±0.66 
- 
89±0.43 80±0.88 68±0.55 69±0.24 72±0.28 58±0.21 67±0.87 
8 - 
- 
97±0.55 98±0.75 83±0.61 82±0.78 86±0.95 67±0.61 73±0.56 
10 - 
- 
- 
- 
- 
- 
98.3±0.24 95±0.94 - 
- 
75±0.54 79±0.21 
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Fig 6.8 Graph representing Cumulative % Drug Release of drug SR layer of Trials F1-F8 
formulations 
Tab 6.8 Cumulative percentage of drug Release of aceclofenac IR layer of  
 F1-F8 formulated with different disintegrants 
TIME 
(min) 
F1 F2 F3 F4 F5 F6 F7 F8 
5 15±0.25 18±0.66 20±0.34 13±0.64 18±0.55 23±0.25 15±0.54 14±0.34 
10 24±0.34 29±0.84 34±0.64 23±0.51 29±0.42 36±0.45 22±0.61 24±0.61 
15 30±0.61 40±0.55 43±0.51 32±0.84 39±0.31 43±0.31 31±0.03 33±0.01 
20 39±0.24 48±0.45 52±0.35 42±0.94 46±0.51 52±0.61 40±0.61 42±0.35 
30 48±0.84 63±0.87 69±0.84 50±0.61 68±0.94 73±0.94 49±0.02 53±0.21 
45 68±0.55 77±0.95 80±0.22 67±0.37 81±0.64 90±0.21 59±0.21 65±0.02 
60 80±0.64 84±0.25 92±0.34 80±0.55 89±0.34 101±0.04 72±0.84 78±0.80 
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Fig. 6.9(a) Graph representing Cumulative % Drug Release of Model drug IR layer of 
Trials F1-F4 formulated with different disintegrants within one hour 
 
 
Fig. 6.9(b) Graph representing Cumulative % Drug Release of Model drug IR layer of 
Trials F5-F8 formulated with different disintegrants within one hour 
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Tab 6.9 shows kinetics behaviour of different formulations famotidine SR layer of  
formulations F1-F8  
 
 
 
 
 
 
R2 Regression coefficient 
Kinetic 
order 
F1 
 
F2 F3 F4 F5 F6 F7 F8 
Zero-
order 
0.910 0.829 0.908 0.928 0.931 0.953 0.966 0.920 
First-
order 
0.913 0.970 0.9610 0.998 0.991 0.976 0.967 0.963 
Higuchi 
0.974 0.990 0.984 0.968 0.956 0.956 0.872 0.835 
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Dissolution test 
The results of in-vitro drug release studies in phosphate buffer (from 3 to 10 hours) are presented 
in tab 6.7 and Fig.6.8. Initially our aim was to select optimum concentration of HPMC of 
different grades for SR layer and optimum concentration of Starch (Disintegrant) for IR layer.  
Hence the tablets containing, 
 SR layer of drug (famotidine) were prepared by altering the concentration of different 
polymers HPMC and guar gum  
 IR layer of drug (aceclofenac) were prepared by altering the concentration of cross 
povidone, croscarmellose sodium and sodium starch glycolate.  
 
Discussion for in-vitro release of drug layer SR  
From the table, it was confirmed that the formulations of F1- F8 of SR layer does not fulfill the 
sustained release theory, In that the HPMC and guar gum were used separately in the 
formulations, but increasing the polymer concentration, it was clearly identified that the drug 
release was retarded. And also from the table, it was also confirmed that the formulation made 
with HPMC (F1 to F3) releases the drug in less amount compared to the formulation made with 
guar gum (F6 to F8), since its viscosity is somewhat higher than guar gum. 
In order to produce optimized formulation, both the Polymers were used together in formulations 
of remaining trials. Yet the formulation F7 of famotidine SR layer made of both HPMC and guar 
gum was not attained the sustained release. The formulations F8 was made with same 
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concentration as that of F3 with little altering in binder concentration. But there was no major 
change in drug release and also the hardness of the tablet goes beyond the limit. 
The next formulation F4 of famotidine SR layer made of HPMC 40(%) and guar gum (20%) 
sustained the drug release up to 12th hour ( not shown in Table) and also the release was similar 
to that of marketed sample. When the concentration of HPMC and guar gum was again increased 
for the formulation F5, the drug from the tablet was very hard to release 
So formulation F4 made of 140mg of HPMC and 140mg of guar gum was considered as 
optimized formulation for SR layer.   
The drug release kinetic study indicated that the release data was best fitted with first order 
kinetics. Higuchi equation explains the diffusion controlled release of the drug through SR 
tablets. 
Discussion for Invitro release of  drug IR layer: 
Then for the tablet of IR layer, 8 trials were made. In those trials, the formulation (Trial F6 of 
aceclofenac layer) made with crosscarmellose sodium 5% (12.5mg) released the drug with in one 
hour and also has the sufficient hardness and friability than other formulations. So the formula 
made for formulation F6 of aceclofenac layer was considered as optimized formulation and that 
formula was used for preparing of famotidine SR layer to produce the Bilayered floating tablet.  
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6.8 Stability study 
The stability study was carried out on optimum formulation F6, and its results reflect that there is 
no significant change in dissolution profile, drug content and bilayer tablets of the formulation. 
Hence, it concludes that the tablets from this formulation are stable for the period 3 months at 40 
±2°C.  
 
Tab 6.10 Stability studies of optimized formulation 
Parameters 1st month 2nd month 3rd month 
Physical appearance No Change No Change No Change 
Swelling index 70.51±0.60 69.76±0.60 69.48±0.3 
Drug content 98.70±0.47 98.63±0.116 99.43±0.101 
In-vitro drug  release 95.57±0.53 100.49±0.55 99.43±0.79 
All values are expressed as Mean±SD 
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7. SUMMARY AND CONCLUSION 
 
 The Bilayered floating tablets containing famotidine SR and aceclofenac IR were 
successfully prepared by wet granulation method. 
  
 The physiochemical evaluation results for the granules of all trials pass the official limits 
in angle of repose, compressibility index and drug content 
 
 The prepared granules also maintained the physiochemical properties of tablets such as 
thickness, hardness, weight variation, friability and drug content. The optimized 
formulation contains the average thickness of 5.4±0.042, average hardness of 6.4±0.14, 
average weight of 600±0.56, friability of 0.021 and 99.72% of drug content. 
 
 In the 8 trials, the optimized formulation was F4 trial which releases the famotidine in 
sustained manner similar to the release given by marketed famotidine SR sample i.e., in 
1st hour it releases 19 % but the remaining drug release was sustained up to 12 hours and 
the same formulation which releases the aceclofenac immediately with in an hour since 
the tablet disintegrated with in 15 minutes. 
 
 The optimized tablets of formulation F4 were selected for stability studies and they were 
kept in two different temperatures. The stability studies confirmed that there was no 
significant difference over a stability testing period. 
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“Hence it may be summarized that the formulation F4 prepared by wet granulation 
method might be a perfect and effective formulation for the treatment.  
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